Press Releases Replimune Group, Inc.

Stocks

REPL

US76029N1063

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:07:04 17/07/2026 BST			5-day change	1st Jan Change
10.08 ^USD	+5.93%		-8.19%	+3.81%

06-30	BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1	MT
06-29	Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating	MT

Press Releases

06-29	Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update	AQ
06-26	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	AQ
05-31	Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting	AQ
05-30	Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting	GL
05-29	Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA	AQ
04-27	Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
04-23	Replimune : RP1 + Nivolumab in Patients with NMSC at EADO 2026	PU
04-23	Replimune : RP1 + Nivolumab in Patients with Anti–PD-1–Failed Melanoma at EADO 2026	PU
04-13	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma	AQ
04-10	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma	AQ
03-02	Replimune to Present at Two Upcoming Investor Conferences	AQ
02-03	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update	AQ
01-14	Replimune : JP Morgan Healthcare Conference 2026 Presentation	PU
12-18	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
11-07	Replimune : IGNYTE Trial Biomarker and Updated Clinical Data Presentation at SITC 2025	PU
11-07	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)	AQ
11-07	Replimune : RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Melanoma at SITC 2025	PU
11-07	Replimune : RP1 + Nivolumab in Patients with and without prior BRAF-Directed Therapy at SITC 2025	PU
11-06	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
20/10/25	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma	AQ
19/10/25	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025	AQ
18/10/25	Replimune : RP1 + Nivolumab in Patients with NMSC at ESMO 2025	PU
18/10/25	Replimune : RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Acral Melanoma at ESMO 2025	PU
22/09/25	Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPL	PR
20/09/25	Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman	PR